SGRY Relative Valuation
SGRY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SGRY is overvalued; if below, it's undervalued.
Historical Valuation
Surgery Partners Inc (SGRY) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -329.83. The fair price of Surgery Partners Inc (SGRY) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：17.04
Fair
28.04
PE
1Y
3Y
5Y
Trailing
Forward
13.36
EV/EBITDA
Surgery Partners Inc. (SGRY) has a current EV/EBITDA of 13.36. The 5-year average EV/EBITDA is 18.07. The thresholds are as follows: Strongly Undervalued below 10.96, Undervalued between 10.96 and 14.52, Fairly Valued between 21.63 and 14.52, Overvalued between 21.63 and 25.19, and Strongly Overvalued above 25.19. The current Forward EV/EBITDA of 13.36 falls within the Undervalued range.
16.59
EV/EBIT
Surgery Partners Inc. (SGRY) has a current EV/EBIT of 16.59. The 5-year average EV/EBIT is 19.86. The thresholds are as follows: Strongly Undervalued below 14.88, Undervalued between 14.88 and 17.37, Fairly Valued between 22.35 and 17.37, Overvalued between 22.35 and 24.84, and Strongly Overvalued above 24.84. The current Forward EV/EBIT of 16.59 falls within the Undervalued range.
0.63
PS
Surgery Partners Inc. (SGRY) has a current PS of 0.63. The 5-year average PS is 1.24. The thresholds are as follows: Strongly Undervalued below 0.46, Undervalued between 0.46 and 0.85, Fairly Valued between 1.64 and 0.85, Overvalued between 1.64 and 2.03, and Strongly Overvalued above 2.03. The current Forward PS of 0.63 falls within the Undervalued range.
5.30
P/OCF
Surgery Partners Inc. (SGRY) has a current P/OCF of 5.30. The 5-year average P/OCF is -168.54. The thresholds are as follows: Strongly Undervalued below -1850.21, Undervalued between -1850.21 and -1009.38, Fairly Valued between 672.30 and -1009.38, Overvalued between 672.30 and 1513.13, and Strongly Overvalued above 1513.13. The current Forward P/OCF of 5.30 falls within the Historic Trend Line -Fairly Valued range.
6.06
P/FCF
Surgery Partners Inc. (SGRY) has a current P/FCF of 6.06. The 5-year average P/FCF is 5.65. The thresholds are as follows: Strongly Undervalued below -169.81, Undervalued between -169.81 and -82.08, Fairly Valued between 93.38 and -82.08, Overvalued between 93.38 and 181.10, and Strongly Overvalued above 181.10. The current Forward P/FCF of 6.06 falls within the Historic Trend Line -Fairly Valued range.
Surgery Partners Inc (SGRY) has a current Price-to-Book (P/B) ratio of 1.26. Compared to its 3-year average P/B ratio of 1.85 , the current P/B ratio is approximately -31.92% higher. Relative to its 5-year average P/B ratio of 3.65, the current P/B ratio is about -65.37% higher. Surgery Partners Inc (SGRY) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 4.62%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 4.29% , the current FCF yield is about -100.00% lower.
1.29
P/B
Median3y
1.85
Median5y
3.65
8.87
FCF Yield
Median3y
4.62
Median5y
4.29
Competitors Valuation Multiple
The average P/S ratio for SGRY's competitors is 0.00, providing a benchmark for relative valuation. Surgery Partners Inc Corp (SGRY) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 6.63%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of SGRY decreased by 17.90% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 0.83 to 3.08.
The secondary factor is the Revenue Growth, contributed 6.63%to the performance.
Overall, the performance of SGRY in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Surgery Partners Inc (SGRY) currently overvalued or undervalued?
What is Surgery Partners Inc (SGRY) fair value?
How does SGRY's valuation metrics compare to the industry average?
What is the current P/B ratio for Surgery Partners Inc (SGRY) as of Dec 05 2025?
What is the current FCF Yield for Surgery Partners Inc (SGRY) as of Dec 05 2025?
What is the current Forward P/E ratio for Surgery Partners Inc (SGRY) as of Dec 05 2025?